Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.52 |
| ▸ | GRM5 | P41594 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13907278 | 0.84 | CYP2A6 (0.62) | GRM5CHRNB2CHRNA4CYP2A6CYP2C9 | |
| Hydrochloric Acid SCHEMBL1476841 | 0.81 | GRM5 (0.54) | GRM5KCNH2CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3796332 | 0.80 | CYP2A6 (0.67) | GRM5CHRNB2CHRNA4CYP2A6CYP2C9 | |
| SCHEMBL3837529 | 0.79 | GRM5 (0.62) | GRM5CHRNB2CHRNA4CYP2A6CYP2C9 | |
| SCHEMBL2524456 | 0.79 | APP (0.61) | APPGRM5KCNH2CYP2C9CYP2C19 | |
| SCHEMBL1120921 | 0.79 | CSF1R (0.47) | GRM5KCNH2CHRNB2CHRNA4CYP2A6 | |
| SCHEMBL401836 | 0.78 | GRM5 (0.64) | APPGRM5CHRNB2CHRNA4CYP2A6 | |
| SCHEMBL5552160 | 0.78 | APP (0.65) | APPKCNH2CHRNB2CHRNA4FFAR1 | |
| SCHEMBL31673222 | 0.78 | GRM5 (0.64) | APPGRM5CHRNB2CHRNA4CYP2A6 | |
| SCHEMBL4309705 | 0.78 | HAO1 (0.45) | GRM5CHRNB2CHRNA4CYP2A6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107011323-A | Metal enzyme inhibitor compound | 威尔金制药有限公司 | 2017-08-04 | — | — | CN | claimed |
| EP-2173716-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI SA (FR) | 2014-03-19 | — | — | EP | claimed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | claimed |
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | claimed |
| EP-2173716-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | claimed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | claimed |
| CN-107011323-A | Metal enzyme inhibitor compound | 威尔金制药有限公司 | 2017-08-04 | — | — | CN | disclosed |
| CN-104203936-B | Metalloenzyme inhibitor compounds | 威尔金制药有限公司 | 2017-04-19 | — | — | CN | disclosed |
| EP-2173716-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI SA (FR) | 2014-03-19 | — | — | EP | disclosed |
| EP-2173716-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI SA (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | APP 1367/4885GRM5 4631/4885KCNH2 4076/4885 |
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | DDT, TYR, DDC | APP 4710/4885GRM5 4419/4885KCNH2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.